<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
    <channel>
        <title>Nova Reader - Subject</title>
        <link>https://www.novareader.co</link>
        <description>Default RSS Feed</description>
        <language>en-us</language>
        <copyright>Newgen KnowledgeWorks</copyright>
        <item>
            <title><![CDATA[Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765996115044-7d3daec1-7620-42f4-a948-1a03a950b603/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1161/HYPERTENSIONAHA.120.15398</link>
            <description><![CDATA[<p class="para" id="N65540">Supplemental Digital Content is available in the text.</p><p class="para" id="N65539">Kidney donation reduces renal function by ≈30% allowing study of the cardiovascular effects of a reduced estimated glomerular filtration rate without comorbidities. We report 5-year results of a longitudinal, parallel-group, blinded end-point study of living kidney donors (n=50) and healthy controls (n=45). The primary end point, left ventricular mass, was measured using cardiac magnetic resonance. Secondary end points, 24-hour ambulatory blood pressure, and pulse wave velocity were measured using validated blood pressure monitors and the SphygmoCor device. Effect sizes were calculated as differences between change from baseline in the donor and control groups. In donors, estimated glomerular filtration rate was 95±15 mL/min per 1.73 m2 at baseline (predonation) and 67±14 mL/min per 1.73 m2 at 5 years. In controls, there was a −1±2 mL/min per 1.73 m2 decline per annum. Change in left ventricular mass at 5 years was not significantly different between donors and controls (mean difference, +0.40 g [95% CI, −4.68 to 5.49] <i>P</i>=0.876), despite an initial increase in mass in donors compared with controls at 12 months. Pulse wave velocity, which increased in donors at 12 months, returned to levels not different from controls at 5 years (mean difference, −0.24 m/s [95% CI, −0.69 to 0.21]). Change in ambulatory systolic blood pressure was not different in donors compared with controls (mean difference, +1.91 mm Hg [95% CI, −2.72 to 6.54]). We found no evidence that the reduction in estimated glomerular filtration rate after kidney donation was associated with a change in left ventricular mass detectable by magnetic resonance imaging at 5 years.</p>]]></description>
            <pubDate><![CDATA[2021-02-08T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The 2020 “WHO Technical Specifications for Automated Non-Invasive Blood Pressure Measuring Devices With Cuff”]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765900897428-c8ef2bf7-63ec-4086-b455-0819c6c595fc/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1161/HYPERTENSIONAHA.120.16625</link>
            <description><![CDATA[<p class="para" id="N65539">High systolic blood pressure (BP) is the single leading modifiable risk factor for death worldwide. Accurate BP measurement is the cornerstone for screening, diagnosis, and management of hypertension. Inaccurate BP measurement is a leading patient safety challenge. A recent World Health Organization report has outlined the technical specifications for automated noninvasive clinical BP measurement with cuff. The report is applicable to ambulatory, home, and office devices used for clinical purposes. The report recommends that for routine clinical purposes, (1) automated devices be used, (2) an upper arm cuff be used, and (3) that only automated devices that have passed accepted international accuracy standards (eg, the International Organization for Standardization 81060-2; 2018 protocol) be used. Accurate measurement also depends on standardized patient preparation and measurement technique and a quiet, comfortable setting. The World Health Organization report provides steps for governments, manufacturers, health care providers, and their organizations that need to be taken to implement the report recommendations and to ensure accurate BP measurement for clinical purposes. Although, health and scientific organizations have had similar recommendations for many years, the World Health Organization as the leading governmental health organization globally provides a potentially synergistic nongovernment government opportunity to enhance the accuracy of clinical BP assessment.</p>]]></description>
            <pubDate><![CDATA[2021-02-01T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Prediction of Cardiovascular Events by Type I Central Systolic Blood Pressure]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765846349915-d8e0cfe3-39b7-41be-9b77-a34cfd70ecf0/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1161/HYPERTENSIONAHA.120.16163</link>
            <description><![CDATA[<p class="para" id="N65540">Supplemental Digital Content is available in the text.</p><p class="para" id="N65539">Compared with brachial blood pressure (BP), central systolic BP (SBP) can provide a better indication of the hemodynamic strain inflicted on target organs, but it is unclear whether this translates into improved cardiovascular risk stratification. We aimed to assess which of central or brachial BP best predicts cardiovascular risk and to identify the central SBP threshold associated with increased risk of future cardiovascular events. This study included 13 461 participants of CARTaGENE with available central BP and follow-up data from administrative databases but without cardiovascular disease or antihypertensive medication. Central BP was estimated by radial artery tonometry, calibrated for brachial SBP and diastolic BP (type I), and a generalized transfer function (SphygmoCor). The outcome was major adverse cardiovascular events. Cox proportional-hazards models, differences in areas under the curves, net reclassification indices, and integrated discrimination indices were calculated. Youden index was used to identify SBP thresholds. Over a median follow-up of 8.75 years, 1327 major adverse cardiovascular events occurred. The differences in areas under the curves, net reclassification indices, and integrated discrimination indices were of 0.2% ([95% CI, 0.1–0.3] <i>P</i>&lt;0.01), 0.11 ([95% CI, 0.03–0.20] <i>P</i>=0.01), and 0.0004 ([95% CI, −0.0001 to 0.0014] <i>P</i>=0.3), all likely not clinically significant. Central and brachial SBPs of 112 mm Hg (95% CI, 111.2–114.1) and 121 mm Hg (95% CI, 120.2–121.9) were identified as optimal BP thresholds. In conclusion, central BP measured with a type I device is statistically but likely not clinically superior to brachial BP in a general population without prior cardiovascular disease. Based on the risk of major adverse cardiovascular events, the optimal type I central SBP appears to be 112 mm Hg.</p>]]></description>
            <pubDate><![CDATA[2020-12-14T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Intrinsic Frequencies of Carotid Pressure Waveforms Predict Heart Failure Events]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765822431653-a9c43ea0-22a4-47bd-83bb-8c26ed41ed28/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1161/HYPERTENSIONAHA.120.15632</link>
            <description><![CDATA[<p class="para" id="N65540">Supplemental Digital Content is available in the text.</p><p class="para" id="N65539">Intrinsic frequencies (IFs) derived from arterial waveforms are associated with cardiovascular performance, aging, and prevalent cardiovascular disease (CVD). However, prognostic value of these novel measures is unknown. We hypothesized that IFs are associated with incident CVD risk. Our sample was drawn from the Framingham Heart Study Original, Offspring, and Third Generation Cohorts and included participants free of CVD at baseline (N=4700; mean age 52 years, 55% women). We extracted 2 dominant frequencies directly from a series of carotid pressure waves: the IF of the coupled heart and vascular system during systole (ω<sub>1</sub>) and the IF of the decoupled vasculature during diastole (ω<sub>2</sub>). Total frequency variation (Δω) was defined as the difference between ω<sub>1</sub> and ω<sub>2</sub>. We used Cox proportional hazards regression models to relate IFs to incident CVD events during a mean follow-up of 10.6 years. In multivariable models adjusted for CVD risk factors, higher ω<sub>1</sub> (hazard ratio [HR], 1.14 [95% CI], 1.03–1.26]; <i>P</i>=0.01) and Δω (HR, 1.16 [95% CI, 1.03–1.30]; <i>P</i>=0.02) but lower ω<sub>2</sub> (HR, 0.87 [95% CI, 0.77–0.99]; <i>P</i>=0.03) were associated with higher risk for incident composite CVD events. In similarly adjusted models, higher ω<sub>1</sub> (HR, 1.23 [95% CI, 1.07–1.42]; <i>P</i>=0.004) and Δω (HR, 1.26 [95% CI, 1.05–1.50]; <i>P</i>=0.01) but lower ω<sub>2</sub> (HR, 0.81 [95% CI, 0.66–0.99]; <i>P</i>=0.04) were associated with higher risk for incident heart failure. IFs were not significantly associated with incident myocardial infarction or stroke. Novel IFs may represent valuable markers of heart failure risk in the community.</p>]]></description>
            <pubDate><![CDATA[2021-01-04T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765822195593-369a9b72-8b38-4a2e-bf4f-cd72817e93b1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1161/HYPERTENSIONAHA.120.14591</link>
            <description><![CDATA[<p class="para" id="N65539">This review portrays how ambulatory blood pressure (BP) monitoring was established and recommended as the method of choice for the assessment of BP and for the rational use of antihypertensive drugs. To establish much-needed diagnostic ambulatory BP thresholds, initial statistical approaches evolved into longitudinal studies of patients and populations, which demonstrated that cardiovascular complications are more closely associated with 24-hour and nighttime BP than with office BP. Studies cross-classifying individuals based on ambulatory and office BP thresholds identified white-coat hypertension, an elevated office BP in the presence of ambulatory normotension as a low-risk condition, whereas its counterpart, masked hypertension, carries a hazard almost as high as ambulatory combined with office hypertension. What clinically matters most is the level of the 24-hour and the nighttime BP, while other BP indexes derived from 24-hour ambulatory BP recordings, on top of the 24-hour and nighttime BP level, add little to risk stratification or hypertension management. Ambulatory BP monitoring is cost-effective. Ambulatory and home BP monitoring are complimentary approaches. Their interchangeability provides great versatility in the clinical implementation of out-of-office BP measurement. We are still waiting for evidence from randomized clinical trials to prove that out-of-office BP monitoring is superior to office BP in adjusting antihypertensive drug treatment and in the prevention of cardiovascular complications. A starting research line, the development of a standardized validation protocol for wearable BP monitoring devices, might facilitate the clinical applicability of ambulatory BP monitoring.</p>]]></description>
            <pubDate><![CDATA[2021-01-04T00:00]]></pubDate>
        </item>
    </channel>
</rss>